Volume 31, No 9, Sep 2021

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 31 Issue 9, September 2021: 1028-1031

LETTERS TO THE EDITOR

Pharmacological inhibition of SRC-1 phase separation suppresses YAP oncogenic transcription activity

Guangya Zhu^1,2 , Jingjing Xie^1,2 , Zhenzhen Fu¹ , Mingliang Wang³ , Qichen Zhang⁴ , Hao He⁵ , Zijun Chen⁵ , Xin Guo⁵ , Jidong Zhu^1,5,*

¹Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201203, China
²University of Chinese Academy of Sciences, Beijing 100049, China
³Department of Natural Products Chemistry, Fudan University, Shanghai 201203, China
⁴Department of Gastroenterology, Changhai Hospital, Navy Medical University, Shanghai 201203, China
⁵Etern Biopharma Co., Ltd., Shanghai 201203, China
These authors contributed equally: Guangya Zhu, Jingjing Xie Correspondence: Jidong Zhu(zhujd@sioc.ac.cn)

Dear Editor,

Yes-associated protein (YAP) is a transcriptional coactivator that plays an essential role in promoting cell proliferation, development and stem cell fate.1 Aberrant YAP activation is prevalent in diverse types of human solid cancers.2 In mammals, a kinase cascade including MST1/2 and LATS1/2 phosphorylates YAP to prevent its nuclear translocation and subsequent interaction with the TEA domain transcription factors TEAD1–4 in the canonical Hippo pathway. Previous studies have intensively emphasized the upstream signals from the Hippo kinase cascade that regulates YAP;1,3 however, the epigenetic regulatory mechanism of YAP transcriptional activity is far less understood. Given the importance of YAP in cancer progression and limited druggability of YAP/TEAD as transcriptional factors, identification of YAP proximal regulators is of great importance to develop new therapeutic strategies for the treatment of cancer.

https://doi.org/10.1038/s41422-021-00504-x

FULL TEXT | PDF

Browse 1150